UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 410, 2022

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		1-11388		04-3153858
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

345 Inverness Drive South, Building B, Suite 250 Englewood, Colorado		80112
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (720) 696-8100

Securities registered pursuant to Section 12(b) of the Act:

	Title of each class	Trading symbol(s)	Name of each exchange on which registered
	Common Stock	VIVE	Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 72.0102. ~~Regulation~~Results FDof ~~Disclosure~~Operations and Financial Conditions.

On ~~October~~November 410, 2022, Viveve Medical, Inc. (the “Company”) issued a press release ~~entitled~~announcing ~~“Viveve~~its ~~Announces~~results ~~Notice of Allowance~~ for ~~Second~~the ~~U.S.~~fiscal ~~Methods~~quarter ~~Patent~~ended ~~for~~September ~~Treating~~30, ~~Female Stress Urinary Incontinence”~~2022. A copy of the Company’s press release is furnished ~~herewith~~ as Exhibit 99.1 to this Current Report on Form 8-K ~~and incorporated herein by reference~~.

The information in Item 72.0102 of this Current Report on Form 8-K, including Exhibit 99.1 ~~attached hereto~~, is being furnished and shall not be deemed “filed” for ~~the~~ purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that ~~Section~~section, nor shall it be deemed ~~subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed~~ incorporated by reference ~~into~~in any filing ~~of the Company~~ under the Securities Act of 1933, as amended, or the Exchange Act, ~~whether made before or after the date hereof,~~ regardless of any general incorporation language in such a filing., ~~The~~except ~~furnishing~~as ~~of this information hereby~~ shall ~~not~~ be ~~deemed~~expressly anset ~~admission~~forth asby tospecific ~~the~~reference ~~materiality~~in ~~of any~~ such ~~information~~a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by the Company on ~~October~~November 410, 2022, ~~furnished~~announcing ~~herewith~~results for the fiscal quarter ended September 30, 2022.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 4, 2022	Viveve Medical, Inc.
Date: November 10, 2022	Viveve Medical, Inc.
	By:	/s/ Scott Durbin
		Scott Durbin
		Chief Executive Officer

Filing Compare · VIVEVE MEDICAL, INC.